1. The use of sage root multicorne (Radix Salviae Miltiorrhizae) or its preparations in the manufacture of medicines for the treatment of diseases associated with liver fibrosis. 2. The use according to claim 1, characterized in that the said preparations include tablets of the sage root of multicorne (Radix Salviae Miltiorrhizae), capsules of the root of sage of the multicorneal (Radix Salviae Miltiorrhizae), dragee tablets of the sage of the root of multicorneal (Radix Salviae Miltiorrhae. The use according to claim 2, characterized in that the said preparations are dragees of the sage root of multicorne (Radix Salviae Miltiorrhizae). 4. The use according to any one of claims 1 to 3, characterized in that said diseases associated with liver fibrosis include liver cirrhosis, hepatitis, liver cancer. The use according to any one of claims 1 to 3, characterized in that said use includes inhibiting liver damage, reducing the increase in serum ALT, AST levels caused by damage to liver cells. The use according to any one of claims 1 to 3, characterized in that it includes protection of the liver function, increasing the synthesis of TP and ALB when the liver function is damaged. The use according to any one of claims 1 to 3, characterized in that it includes inhibiting the activation of proliferation of stellate liver cells, reducing the expression of α-SMA in liver tissue. The use according to any one of claims 1 to 3, characterized in that it includes increasing SOD activity in the liver tissue, reducing the expression of MDA, so as to inhibit the activation of stellate cells of the liver. The use according to any one of claims 1 to 3, characterized in that it includes inhibition of the displacement of the extracellular matrix of liver cells and an increase in collagen, a decrease in the content of collagen type IV in serum, a decrease in the level of Hyp in the liver tissue. The use according to any one of claims 1 to 3, characterized in that its use includes inhibit
